锯齿状息肉与异时性结直肠进展期肿瘤风险:系统评价与Meta分析
该系统评价与Meta分析纳入11项研究、1,079,315例患者,评估锯齿状息肉(SPs)与异时性进展期结直肠肿瘤(ACRN)风险。结果显示,单纯SPs或单纯无蒂锯齿状病变(SSLs)与单纯传统腺瘤患者的异时性ACRN和结直肠癌风险无显著差异;但同步存在SPs(或SSLs)与高危腺瘤(HRAs)的患者异时性ACRN风险高于单纯HRAs患者。结论支持现行指南对SSLs与传统腺瘤采用相似监测间期的推荐,并提示同步SPs(或SSLs)与HRAs患者风险增加,需进一步研究是否需更密集监测。
要点
- 单纯SPs或SSLs与单纯传统腺瘤的异时性ACRN及结直肠癌风险无显著差异。
- 同步SPs+HRAs者异时性ACRN风险高于单纯HRAs者(OR 1.64)。
- 同步SSLs+HRAs者异时性ACRN风险高于单纯HRAs者(OR 3.10)。
核心结论
- Meta分析结果支持现行指南对SSLs与传统腺瘤推荐相似监测间期的做法。
- 同步SPs(或SSLs)与HRAs患者异时性ACRN风险似乎增加,需进一步研究确定是否需更密集监测。
研究设计与样本
- 系统评价与Meta分析,检索截至2020年8月发表的所有相关研究。
- 共纳入11项研究、1,079,315例患者。
主要发现
- 单纯SPs组与单纯传统腺瘤组异时性ACRN风险无显著差异(OR 0.70,95%CI 0.27-1.82),CRC风险无显著差异(OR 0.74,95%CI 0.47-1.14)。
- 单纯SSLs组与单纯传统腺瘤组异时性ACRN风险无显著差异(OR 0.91,95%CI 0.23-3.63),CRC风险无显著差异(OR 1.11,95%CI 0.42-2.97)。
- 同步SPs+HRAs组异时性ACRN风险高于单纯HRAs组(OR 1.64,95%CI 1.21-2.24)。
- 同步SSLs+HRAs组异时性ACRN风险高于单纯HRAs组(OR 3.10,95%CI 1.92-4.99)。
- 同步SPs(或SSLs)与低风险腺瘤组和单纯低风险腺瘤组之间异时性ACRN风险无差异。
关键数值与推荐
- 单纯SPs vs 单纯传统腺瘤:异时性ACRN的OR 0.70(95%CI 0.27-1.82),CRC的OR 0.74(95%CI 0.47-1.14)。
- 单纯SSLs vs 单纯传统腺瘤:异时性ACRN的OR 0.91(95%CI 0.23-3.63),CRC的OR 1.11(95%CI 0.42-2.97)。
- 同步SPs+HRAs vs 单纯HRAs:异时性ACRN的OR 1.64(95%CI 1.21-2.24)。
- 同步SSLs+HRAs vs 单纯HRAs:异时性ACRN的OR 3.10(95%CI 1.92-4.99)。
临床怎么用
- 现行指南推荐SSLs与传统腺瘤采用相似监测间期,本Meta分析结果支持该推荐。
- 同步SPs(或SSLs)与HRAs患者异时性ACRN风险似乎增加,作者认为需进一步研究确定是否需更密集监测。
局限性
- 上述比较中识别到显著异质性。
- 作者指出需进一步研究以确定同步SPs(或SSLs)与HRAs患者是否需更密集监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Surveillance recommendations for serrated polyps (SPs) are based on insufficient evidence. We aimed to evaluate the risk of metachronous advanced colorectal neoplasia (ACRN) associated with SPs. METHODS: We searched all relevant studies published through August 2020 that examined the risk of SPs for developing metachronous lesions. We performed meta-analyses of the risk of metachronous ACRN or colorectal cancer (CRC) between patients with SPs (or sessile serrated lesions [SSLs]) alone and those with conventional adenomas alone, and between patients with synchronous SPs (or SSLs) and conventional adenomas and those with conventional adenomas alone. RESULTS: Eleven studies with 1,079,315 patients were included in the meta-analysis. No significant differences in the risks of metachronous ACRN and CRC were found between the SPs alone and conventional adenomas alone groups (odds ratio [OR] [95% confidence interval [CI]]: ACRN, 0.70 [0.27-1.82]; CRC, 0.74 [0.47-1.14]). The risks were similar between SSLs alone and conventional adenomas alone (OR [95% CI]: ACRN, 0.91 [0.23-3.63]; CRC, 1.11 [0.42-2.97]). Significant heterogeneity was identified in these comparisons. Synchronous SPs (or SSLs) and high-risk adenomas (HRAs) had a higher risk of metachronous ACRN than HRAs alone (OR [95% CI]: SPs+HRAs, 1.64 [1.21-2.24]; SSLs+HRAs, 3.10 [1.92-4.99]); however, there was no difference in the risk between synchronous SPs (or SSLs) and low-risk adenomas and low-risk adenomas alone. CONCLUSIONS: The results of this meta-analysis support the current guidelines, which recommend similar surveillance intervals for SSLs and conventional adenomas. Patients with synchronous SPs (or SSLs) and HRAs appear to be at an increased risk of metachronous ACRN, and further studies are needed to determine whether they require more intensive surveillance.
引用
- Jung YS, Park JH, Park CH, et al. Serrated Polyps and the Risk of Metachronous Colorectal Advanced Neoplasia: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2020. PMID: 33007512. doi:10.1016/j.cgh.2020.09.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。